These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 24053892)

  • 1. Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion.
    Sophie R; Hafiz G; Scott AW; Zimmer-Galler I; Nguyen QD; Ying H; Do DV; Solomon S; Sodhi A; Gehlbach P; Duh E; Baranano D; Campochiaro PA
    Am J Ophthalmol; 2013 Oct; 156(4):693-705. PubMed ID: 24053892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study.
    Campochiaro PA; Sophie R; Pearlman J; Brown DM; Boyer DS; Heier JS; Marcus DM; Feiner L; Patel A;
    Ophthalmology; 2014 Jan; 121(1):209-219. PubMed ID: 24112944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scatter Photocoagulation Does Not Reduce Macular Edema or Treatment Burden in Patients with Retinal Vein Occlusion: The RELATE Trial.
    Campochiaro PA; Hafiz G; Mir TA; Scott AW; Solomon S; Zimmer-Galler I; Sodhi A; Duh E; Ying H; Wenick A; Shah SM; Do DV; Nguyen QD; Kherani S; Sophie R
    Ophthalmology; 2015 Jul; 122(7):1426-37. PubMed ID: 25972260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in Retinal Nonperfusion Associated with Suppression of Vascular Endothelial Growth Factor in Retinal Vein Occlusion.
    Mir TA; Kherani S; Hafiz G; Scott AW; Zimmer-Galler I; Wenick AS; Solomon S; Han I; Poon D; He L; Shah SM; Brady CJ; Meyerle C; Sodhi A; Linz MO; Sophie R; Campochiaro PA
    Ophthalmology; 2016 Mar; 123(3):625-34.e1. PubMed ID: 26712560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranibizumab Pro Re nata versus Dexamethasone in the Management of Ischemic Retinal Vein Occlusion:
    Pielen A; Feltgen N; Hattenbach LO; Hoerauf H; Bertelmann T; Quiering C; Vögeler J; Priglinger S; Lang GE; Schmitz-Valckenberg S; Wolf A; Rehak M
    Curr Eye Res; 2020 May; 45(5):604-614. PubMed ID: 31665935
    [No Abstract]   [Full Text] [Related]  

  • 6. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.
    Heier JS; Campochiaro PA; Yau L; Li Z; Saroj N; Rubio RG; Lai P
    Ophthalmology; 2012 Apr; 119(4):802-9. PubMed ID: 22301066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Outcomes of Ranibizumab Treatment in French Patients with Visual Impairment due to Macular Edema Secondary to Retinal Vein Occlusion: 24-Month Results from the BOREAL-RVO Study.
    Glacet-Bernard A; Girmens JF; Kodjikian L; Delcourt C; Fajnkuchen F; Creuzot-Garcher C; San Nicolas N; Massin P
    Ophthalmic Res; 2023; 66(1):824-834. PubMed ID: 36972579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion.
    Kim M; Yu SY; Kim ES; Bae SH; Park JH; Yu HG; Kwak HW
    Ophthalmologica; 2012; 227(3):132-8. PubMed ID: 22212151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials.
    Thach AB; Yau L; Hoang C; Tuomi L
    Ophthalmology; 2014 May; 121(5):1059-66. PubMed ID: 24424249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER.
    Tadayoni R; Waldstein SM; Boscia F; Gerding H; Pearce I; Priglinger S; Wenzel A; Barnes E; Gekkieva M; Pilz S; Monés J;
    Ophthalmology; 2016 Jun; 123(6):1332-44. PubMed ID: 27039022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
    Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
    Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reading speed improvements in retinal vein occlusion after ranibizumab treatment.
    Suñer IJ; Bressler NM; Varma R; Lee P; Dolan CM; Ward J; Colman S; Rubio RG
    JAMA Ophthalmol; 2013 Jul; 131(7):851-6. PubMed ID: 23699977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion.
    Babiuch AS; Han M; Conti FF; Wai K; Silva FQ; Singh RP
    JAMA Ophthalmol; 2019 Jan; 137(1):38-46. PubMed ID: 30286219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Retinal Vein Occlusion with Ranibizumab in Clinical Practice: Longer-Term Results and Predictive Factors of Functional Outcome.
    Farinha C; Marques JP; Almeida E; Baltar A; Santos AR; Melo P; Costa M; Figueira J; Cachulo ML; Pires I; Silva R
    Ophthalmic Res; 2015; 55(1):10-8. PubMed ID: 26540281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of anti-VEGF therapy on present day management of macular edema due to BRVO and CRVO: a longitudinal analysis on visual function, injection time interval and complications.
    Papadia M; Misteli M; Jeannin B; Herbort CP
    Int Ophthalmol; 2014 Dec; 34(6):1193-201. PubMed ID: 25245600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Mitry D; Bunce C; Charteris D
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion.
    Tan MH; McAllister IL; Gillies ME; Verma N; Banerjee G; Smithies LA; Wong WL; Wong TY
    Am J Ophthalmol; 2014 Jan; 157(1):237-247.e1. PubMed ID: 24112635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal ranibizumab (Lucentis) for treatment of central retinal vein occlusion: a prospective study.
    Rouvas A; Petrou P; Vergados I; Pechtasides D; Liarakos V; Mitsopoulou M; Ladas I
    Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1609-16. PubMed ID: 19609550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ranibizumab alone versus ranibizumab with targeted retinal laser for branch retinal vein occlusion with macular edema.
    Goel S; Kumar A; Ravani RD; Chandra P; Chandra M; Kumar V
    Indian J Ophthalmol; 2019 Jul; 67(7):1105-1108. PubMed ID: 31238421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term efficacy and safety of ranibizumab for macular oedema secondary to retinal vein occlusion in Japanese patients.
    Kamei M; Terasaki H; Yoshimura N; Shiraga F; Ogura Y; Grotzfeld AS; Pilz S; Ishibashi T
    Acta Ophthalmol; 2017 Feb; 95(1):e29-e35. PubMed ID: 27654837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.